Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.16767
Abstract: Glioblastomas are characterized by amplification of EGFR. Approximately half of tumors with EGFR over-expression also express a constitutively active ligand independent EGFR variant III (EGFRvIII). While current treatments emphasize surgery followed by radiation and chemotherapy… read more here.
Keywords: targeting egfrviii; pdk1 axis; egfrviii pdk1; metabolic targeting ... See more keywords